In our study, the analysis of srm-T-PSA in sequential samples yielded results consistent with expectations: clinical improvement and response to treatment were associated with a significant decrease in serum tumor marker levels, which subsequently increased as the cancer progressed. This evidence concerns the gene KLK3 and neoplasm.